Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$1.12
-0.04 (-3.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $34.5M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$659M
P/E
7.0x
↓EV/EBITDA
2.6x
↓ROE
4.5%
↑Gross Margin
50.8%
↑Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.2%
FCF CAGR
+13.2%
FCF margin
7.1%
FCF / Net income
1.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.44B · net income $91.9M · FCF $101.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.44B | $1.44B | $1.40B | $1.05B | $1.23B |
| Net Income | $91.9M | $91.9M | $93.1M | $16.7M | $51.3M |
| EBITDA | $239.4M | $239.4M | $259.7M | $191.6M | $227.0M |
| EPS | 0.16 | 0.16 | 0.16 | 0.03 | 0.09 |
| Gross Margin | 50.8% | 50.8% | 53.8% | 52.4% | 62.5% |
| Operating Margin | 5.3% | 5.3% | 5.5% | -0.7% | 6.2% |
| Net Margin | 6.4% | 6.4% | 6.7% | 1.6% | 4.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.14 | 0.10 | 0.08 |
| Current Ratio | 1.03 | 1.03 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $101.3M | $101.3M | $34.5M | $-49.6M | $69.8M |
| Returns | |||||
| ROE | 4.5% | 4.5% | 5.6% | 0.8% | 2.7% |
| Valuation | |||||
| P/E | 7.00 | 7.00 | 8.98 | 51.06 | 20.67 |
| EV/EBITDA | 2.59 | 2.59 | 3.26 | 4.63 | 4.56 |
| P/B | 0.32 | 0.32 | 0.51 | 0.42 | 0.55 |
| Growth & Yield | |||||
| Revenue Growth | 2.6% | 2.6% | 32.9% | -14.6% | — |
| EPS Growth | -1.3% | -1.3% | 456.7% | -67.4% | — |
| Dividend Yield | 4.0% | 4.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-14.0%
EPS terminal req.
$0.10
Spread vs growth
12.7%
5Y implied EPS CAGR
-5.1%
EPS terminal req.
$0.12
Spread vs growth
3.8%
10Y implied EPS CAGR
2.2%
EPS terminal req.
$0.19
Spread vs growth
-3.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.2%
Start / end P/E
9.0x → 7.2x
EPS bridge
0.16 → 0.16
Residual
+0.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.